EGFR and non-small cell lung carcinoma: HER2 mutations in NSCLC confer relative resistance to conventional chemotherapy [9], and HER2 amplification is one of the mechanisms of acquired resistance to EGFR TKIs, suggesting that HER2 targeted therapy can be considered as a therapeutic option in NSCLC patients with such HER2 alterations.